Exenatide exerts a potent antiinflammatory effect

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 1, 2012, Pages 198-207

  Chaudhuri, Ajay ^a   Ghanim, Husam ^a   Vora, Mehul ^a   Sia, Chang Ling ^a   Korzeniewski, Kelly ^a   Dhindsa, Sandeep ^a   Makdissi, Antoine ^a   Dandona, Paresh ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; FATTY ACID; GELATINASE B; GLIBENCLAMIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN ASPART; INSULIN GLARGINE; INTERLEUKIN 6; MESSENGER RNA; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; REACTIVE OXYGEN METABOLITE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; MONONUCLEAR CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TREATMENT DURATION;

ANTI-INFLAMMATORY AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FATTY ACIDS, NONESTERIFIED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MIDDLE AGED; OBESITY; PEPTIDES; PLACEBOS; REACTIVE OXYGEN SPECIES; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; VENOMS;

EID: 84855483249     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1508     Document Type: Article

References (37)

1. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR 2001 Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281:E155-E161
2. Barnett AH 2005 Exenatide. Drugs Today (Barc) 41:563-578 (Pubitemid 41810472)
3. MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB 2002 The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 51(Suppl 3):S434-S442 (Pubitemid 35403427)
4. Holz GG, Chepurny OG 2003 Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem 10:2471-2483 (Pubitemid 37236400)
5. Rodriquez de Fonseca F, Navarro M, Alvarez E, Roncero I, Chowen JA, Maestre O, Gómez R, Muñoz RM, Eng J, Blázquez E 2000 Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 49:709-717 (Pubitemid 30354576)
6. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RG, Greig NH, Egan JM 2000 Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141:1936-1941 (Pubitemid 32274340)
7. Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P 2007 Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 13:444-450
8. Varanasi A, Chaudhuri A, Dhindsa S, Arora A, Lohano T, Vora MR, Dandona P 2010 Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein and triglyceride concentrations. Endocr Pract 17:192-200
9. Bunck MC, Diamant M, Eliasson B, Cornér A, Shaginian RM, Heine RJ, Taskinen MR, Yki-Järvinen H, Smith U 2010 Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 33:1734-1737
10. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF 2010 Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther 12:233-240
11. Xue S, Wasserfall CH, Parker M, Brusko TM, McGrail S, McGrail K, Moore M, Campbell-Thompson M, Schatz DA, Atkinson MA, Haller MJ 2008 Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency. Ann NY Acad Sci 1150:152-156
12. Wu JD, Xu XH, Zhu J, Ding B, Du TX, Gao G, Mao XM, Ye L, Lee KO, Ma JH 2011 Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus. Diabetes Technol Ther 13:143-148
13. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H 2010 Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59:1030-1037
14. Koska J, Schwartz EA, Mullin MP, Schwenke DC, Reaven PD 2010 Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care 33:1028-1030
15. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ 2009 GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58:975-983
16. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE 2009 Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 53:501-510
17. Ross R 1999 Atherosclerosis: an inflammatory disease. N Engl J Med 340:115-126
18. Dandona P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D, Nicotera T 1996 Oxidative damage to DNA in diabetes mellitus. Lancet 347:444-445 (Pubitemid 26054071)
19. Andrews NC, Faller DV 1991 A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19:2499
20. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P 2004 Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 110:1564-1571 (Pubitemid 39297977)
21. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S 2001 Insulin inhibits intranuclear nuclear factorκ-B and stimulates Iκ-B in mononuclear cells in obese subjects: evidence for an antiinflammatory effect? J Clin Endocrinol Metab 86:3257-3265 (Pubitemid 32674120)
22. Barnes PJ, Karin M 1997 Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071 (Pubitemid 27163860)
23. Crowe DL, Tsang KJ, Shemirani B 2001 Jun N-terminal kinase 1 mediates transcriptional induction of matrix metalloproteinase 9 expression. Neoplasia 3:27-32 (Pubitemid 32201607)
24. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F 1999 Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 274:10689-10692
25. Hallman M, Rämet M, Ezekowitz RA 2001 Toll-like receptors as sensors of pathogens. Pediatr Res 50:315-321 (Pubitemid 32801954)
26. Li H, Sun B 2007 Toll-like receptor 4 in atherosclerosis. J Cell Mol Med 11:88-95 (Pubitemid 46439627)
27. Bennett BL, Satoh Y, Lewis AJ 2003 JNK: a new therapeutic target for diabetes. Curr Opin Pharmacol 3:420-425 (Pubitemid 36908946)
28. Hotamisligil GS 2006 Inflammation and metabolic disorders. Nature 444:860-867 (Pubitemid 46024993)
29. Ehses JA, Meier DT, Wueest S, Rytka J, Boller S, Wielinga PY, Schraenen A, Lemaire K, Debray S, Van Lommel L, Pospisilik JA, Tschopp O, Schultze SM, Malipiero U, Esterbauer H, Ellingsgaard H, Rütti S, Schuit FC, Lutz TA, Böni-Schnetzler M, Konrad D, Donath MY 2010 Toll-like receptor 2-deficient mice are protected from insulin resistance and β-cell dysfunction induced by a high-fat diet. Diabetologia 53:1795-1806
30. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS 2006 TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116:3015-3025 (Pubitemid 44684486)
31. Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K, Hilton DJ, Hotamisligil GS, Van Obberghen E 2001 SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-α in the adipose tissue of obese mice. J Biol Chem 276:47944-47949
32. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Natoli E, Rollins BJ, Milos PM 1999 Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 19:1518-1525 (Pubitemid 29263023)
33. Galis ZS, Sukhova GK, Lark MW, Libby P 1994 Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94:2493-2503 (Pubitemid 24379627)
34. O'Brien KD, Chait A 2006 Serum amyloid A: the "other" inflammatory protein. Curr Atheroscler Rep 8:62-68 (Pubitemid 43675756)
35. Kim Chung le T, Hosaka T, Yoshida M, Harada N, Sakaue H, Sakai T, Nakaya Y 2009 Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun 390:613-618
36. Varanasi A, Bellini N, Rawal D, Vora M, Makdissi A, Dhindsa S, Chaudhuri A, Dandona P 2011 Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol 165:77-84
37. Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A, Dandona P 2003 Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 52: 2882-2887 (Pubitemid 37466856)